Haemonetics Corporation share price logo

Haemonetics Corporation

NYSE: HAE

Mid Cap

$56.29

-0.83

(-1.45%)

as on

Haemonetics Corporation Stock Performance

as on May 16, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $56.34
    $58.18
    downward going graph

    -0.09%

    Downside

    3.36%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $47.32
    $87.32
    downward going graph

    15.94%

    Downside

    55.13%

    Upside

    downward going graph

Haemonetics Corporation share price movements today

Previous Close
$57.12
Open
$57.32
Volume
605.1K
Day's Low - High
$56.34 - $58.18
52 Week Low - High
$47.32 - $87.32

Haemonetics Corporation Historical Returns

1 Month Return
-7.8 %
3 Month Return
-1.11 %
1 Year Return
-17.67 %
3 Year Return
-35.94 %
5 Year Return
+ 2 %

Haemonetics Corporation Stock Fundamentals & Key Indicators

Check Haemonetics Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.6B

EPS (TTM)

4.9433

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.28%

PE Ratio (TTM)

15.71

Industry PE ratio

14.209090909090909

PEG Ratio

0.8428

EBITDA

362.1M

Revenue (TTM)

1.3B

Profit Margin

7.29%

Return On Equity TTM

12.03%

Haemonetics Corporation Stock Valuation

Track how Haemonetics Corporation P/E has moved over time to understand its valuation trends.

Haemonetics Corporation in the last 5 years

  • Overview

  • Trends

Lowest (13.10x)

March 31, 2026

Industry (14.21x)

May 15, 2026

Today (15.71x)

May 15, 2026

Highest (29.61x)

June 30, 2021

LowHigh

Today’s Price to Earnings Ratio: 15.71x

Haemonetics Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Haemonetics Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.6B2%15.717.29%
BUY$115.8B20.78%34.9613.21%
BUY$78.9B28.88%22.217.29%
BUY$46.8B-9.11%43.9717.39%
BUY$97.8B-38.56%21.2913.00%

Stock Returns calculator for Haemonetics Corporation Stock including INR - Dollar returns

The Haemonetics Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Haemonetics Corporation investment value today

Current value as on today

₹91,005

Returns

-₹8,995

(-8.99%)

Returns from Haemonetics Corporation Stock

-₹18,867 (-18.87%)

Dollar Impact

₹9,873 (+9.87%)

Analyst Recommendation on Haemonetics Corporation Stock

Based on 11 analysts

BUY

72.73%

Buy

27.27%

Hold

0.00%

Sell

Based on 11 analysts, 72.73% of analysts recommend a 'BUY' rating for Haemonetics Corporation. Average target price of $80.2

Haemonetics Corporation Share Price Target

Get share price movements and forecasts by analysts on Haemonetics Corporation.

What analysts predicted

29.81%UPSIDE

Target Price

$80.2

Current Price

$56.29

Analyzed by

11 Analysts

Target

$80.20

Haemonetics Corporation target price $80.2, a slight upside of 29.81% compared to current price of $56.29. According to 11 analysts rating.

Indian Investors' Interest in Haemonetics Corporation Stock

Search interest for Haemonetics Corporation Stock has increased by 125% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:125% versus previous 30 day period

Haemonetics Corporation Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
336
343
336
345
348
330
321
327
338
346
Gross Profit
184
188
179
191
199
193
191
183
191
198
Operating Income
45
29
39
51
59
71
53
67
69
51
EBITDA
82
68
80
88
95
99
93
95
96
51
Interest Expense
1
6
6
6
9
0
4
7
8
5
Depreciation
23
27
29
29
29
28
28
28
27
-
Income Before Tax
44
23
46
44
49
70
45
51
59
-28
Income Tax Expense
12
3
8
10
12
12
11
12
15
-8
Net Income
31
20
38
33
37
57
34
38
44
-20
Net Profit Margin
9.29%
5.93%
11.41%
9.79%
10.76%
17.54%
10.59%
11.82%
13.20%
-5.82%

Haemonetics Corporation Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
886
903
967
988
870
993
1,168
1,309
1,360
1,334
Gross Profit
378
411
417
487
428
530
622
711
778
743
Operating Income
-19
56
83
103
89
80
156
164
221
241
EBITDA
123
153
192
257
184
191
252
295
355
397
Interest Expense
8
4
9
16
16
17
14
13
9
28
Depreciation
-
89
109
110
84
97
93
97
115
-
Income Before Tax
-27
59
73
87
72
63
141
151
212
128
Income Tax Expense
-1
14
18
10
-6
20
26
34
44
30
Net Income
-26
45
55
76
79
43
115
117
167
97
Net Profit Margin
-2.96%
5.04%
5.69%
7.74%
9.13%
4.37%
9.87%
8.98%
12.32%
7.29%

Haemonetics Corporation Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
20
38
33
37
57
34
38
44
-20
Operating Cash Flow
64
-27
48
43
116
17
111
93
70
Investing Cash Flow
-13
-139
-23
-17
18
-33
-30
-29
-86
Financing Cash Flow
-63
333
-74
1
-151
-2
-76
2
-101
Change in Cash
-15
165
-45
21
-14
-13
3
66
-117

Haemonetics Corporation Annual Cash Flow

All numbers in Millions USD

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
45
55
76
79
43
115
117
167
97
Operating Cash Flow
220
159
158
108
172
273
181
181
293
Investing Cash Flow
-63
-116
-57
-425
-86
-143
-322
-161
-179
Financing Cash Flow
-120
-50
-131
367
-15
-100
38
108
-178
Change in Cash
40
-10
-32
54
67
24
-105
127
-61

Global Institutional Holdings in Haemonetics Corporation

Funds
Holdings
Schroder Investment Management Group
1.85%
Allspring Global Investments Holdings, LLC
2.02%
Wellington Management Company LLP
4.46%
Holocene Advisors, LP
2.72%
The Goldman Sachs Group Inc
2.64%

Haemonetics Corporation News & Key Events

    Insights on Haemonetics Corporation

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 4 quarters, 321.39M → 346.35M (in $), with an average increase of 2.5% per quarter

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, HAE stock has moved up by 3.6%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Edwards Lifesciences Corp. has given 4.3% return, outperforming this stock by 23.1%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Haemonetics Corp has experienced a drawdown of -36.0%, however Stryker Corporation resisted the overall trend and outperformed by 27.7%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 44.74M → -20.14M (in $), with an average decrease of 145.0% per quarter

    About Haemonetics Corporation

    Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
    OrganisationHaemonetics Corporation
    Headquarters125 Summer Street, Boston, MA, United States, 02110
    IndustryMedical Devices
    CEOMr. Christopher A. Simon
    E-voting on sharesClick here to vote

    Key Management of Haemonetics Corporation

    Name

    Title

    Ms. Olga Guyette

    Senior Director of Investor Relations

    Ms. Laurie A. Miller

    Senior VP & Chief Human Resources Officer

    Dr. Jan Hartmann M.D.

    Senior VP & Chief Medical Officer

    Ms. Michelle L. Basil Esq., J.D.

    Executive VP, General Counsel & Secretary

    Mr. James C. D'Arecca CPA

    CFO, Executive VP & Financial Officer

    Mr. Roy Galvin

    Executive VP & Chief Commercial Officer

    Mr. Frank W. Chan Ph.D.

    Executive VP & COO

    Ms. Farris Maryanne Maunsell

    VP, Chief Accounting Officer & Principal Accounting Officer

    Mr. Rajeev Varma

    Senior Vice President of Strategy & Corporate Development

    Mr. Christopher A. Simon

    CEO, President & Director

    FAQs

    What is Haemonetics Corporation share price today?

    Haemonetics Corporation share price today is $56.29 as on at the close of the market. Haemonetics Corporation share today touched a day high of $58.18 and a low of $56.34.

    What is the 52 week high and 52 week low for Haemonetics Corporation share?

    Haemonetics Corporation share touched a 52 week high of $87.32 on and a 52 week low of $47.32 on . Haemonetics Corporation stock price today i.e. is closed at $56.29,which is 35.54% down from its 52 week high and 18.97% up from its 52 week low.

    What is Haemonetics Corporation's market capitalisation today?

    Haemonetics Corporation market capitalisation is $0.00T as on .

    How to invest in Haemonetics Corporation Stock (HAE) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Haemonetics Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Haemonetics Corporation Shares that will get you 0.0266 shares as per Haemonetics Corporation share price of $56.29 per share as on May 16, 2026 at 8:46 am IST.

    What is the minimum amount required to buy Haemonetics Corporation Stock (HAE) from India?

    Indian investors can start investing in Haemonetics Corporation (HAE) shares with as little as ₹95.955 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹959.55 in Haemonetics Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on Haemonetics Corporation share’s latest price of $56.29 as on May 16, 2026 at 8:46 am IST, you will get 0.1777 shares of Haemonetics Corporation. Learn more about fractional shares .

    What are the returns that Haemonetics Corporation has given to Indian investors in the last 5 years?

    Haemonetics Corporation stock has given 2% share price returns and 30.42% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?